13.43 USD
+0.44
3.39%
At close Jul 29, 4:00 PM EDT
After hours
13.55
+0.12
0.89%
1 day
3.39%
5 days
6.59%
1 month
23.78%
3 months
-18.66%
6 months
-26.65%
Year to date
-18.11%
1 year
50.73%
5 years
18.74%
10 years
295.00%
 

About: Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Employees: 452

0
Funds holding %
of 7,323 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

123% more call options, than puts

Call options by funds: $2.4M | Put options by funds: $1.07M

53% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 19

40% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 52

22% more capital invested

Capital invested by funds: $591M [Q4 2024] → $718M (+$127M) [Q1 2025]

6.06% more ownership

Funds ownership: 81.46% [Q4 2024] → 87.53% (+6.06%) [Q1 2025]

4% more funds holding

Funds holding: 172 [Q4 2024] → 179 (+7) [Q1 2025]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 4 (-1) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$24
79%
upside
Avg. target
$24
79%
upside
High target
$24
79%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Canaccord Genuity
Caitlin Cronin
79%upside
$24
Buy
Maintained
13 May 2025

Financial journalist opinion

Based on 3 articles about AXGN published over the past 30 days

Neutral
GlobeNewsWire
12 hours ago
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be available for one-on-one investor meetings at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025.
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
Neutral
Zacks Investment Research
17 hours ago
AxoGen (AXGN) Earnings Expected to Grow: Should You Buy?
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Earnings Expected to Grow: Should You Buy?
Neutral
GlobeNewsWire
1 week ago
Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025
ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 second quarter financial results on Tuesday, August 5, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025
Neutral
GlobeNewsWire
2 months ago
Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale, board director, chief executive officer, and president, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference, on Wednesday, June 11, 2025, at 2:00 p.m. ET.
Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference
Negative
Zacks Investment Research
2 months ago
AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Neutral
Seeking Alpha
2 months ago
Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript
Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript
Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
AxoGen (AXGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.06 per share a year ago.
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
Axogen, Inc. Reports 2025 First Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025.
Axogen, Inc. Reports 2025 First Quarter Financial Results
Neutral
GlobeNewsWire
3 months ago
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025
ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter financial results on Thursday, May 8, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025
Neutral
Seeking Alpha
5 months ago
Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript
Axogen, Inc. (NASDAQ:AXGN ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Jens Kemp - Chief Marketing Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer; and Jens Kemp, Chief Marketing Officer.
Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™